Pharvaris (NASDAQ:PHVS) Rating Lowered to “Sell” at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research firms have also commented on PHVS. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citizens Jmp lowered their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Morgan Stanley raised their price objective on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. Finally, Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Price Performance

PHVS stock opened at $34.94 on Friday. Pharvaris has a 52 week low of $19.12 and a 52 week high of $36.60. The company has a fifty day simple moving average of $32.16 and a two-hundred day simple moving average of $29.01. The firm has a market capitalization of $2.29 billion, a P/E ratio of -10.99 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, analysts anticipate that Pharvaris will post -3.2 EPS for the current year.

Insider Activity

In related news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert Glassman sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $29.82, for a total transaction of $298,200.00. Following the completion of the sale, the director directly owned 10,500 shares in the company, valued at $313,110. This trade represents a 48.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 303,356 shares of company stock worth $9,746,065 in the last 90 days. Company insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PHVS. Tudor Investment Corp ET AL purchased a new position in Pharvaris during the 3rd quarter valued at $1,943,000. PSP Research LLC purchased a new stake in Pharvaris in the fourth quarter worth $569,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 710.4% during the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after purchasing an additional 23,743 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Pharvaris during the fourth quarter valued at $1,536,000. Finally, Eversept Partners LP purchased a new stake in shares of Pharvaris during the fourth quarter valued at $12,187,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.